Article

The importance of treating depression, the condition that contributes most to global disability

Live-Med · · Author: Pedro Zuzarte

Image from the original publication: “A importância de tratar a depressão, a patologia que mais contribui para a incapacidade global”

An article by Pedro Zuzarte on the Live-Med blog, from November 2020. It presents depression as the leading cause of disability worldwide and draws on measurable organic changes, such as reduced hippocampal volume, to argue for its treatment as a clinical priority.

Key ideas

  • Depression is presented as the clinical condition likely to cause the greatest overall harm in a person’s life, from loss of quality of life to reduced life expectancy, with personal, social, occupational and family consequences.
  • The text calls the lack of attention it still receives an “unfortunate paradox” and explains it by the old idea of a “functional” illness with no objective organic consequences, and by a medicine increasingly reliant on tests and markers, whereas depression is diagnosed through psychological and behavioural symptoms.
  • It notes that the subject has gained social and medical prominence, and that data on the economic impact of depression, especially in more developed societies, caught political attention and sped up measures in favour of mental health.
  • Research has shown measurable pathophysiological consequences: loss of volume in areas of the hippocampus, links with cognitive deficits and with problems in other systems, such as the cardiovascular system.
  • It concludes that the problem is one of “awareness and education”: depression is an important biopsychosocial problem whose consequences go far beyond the psychological.
Read more

Context

An article published on 27 November 2020 on the Live-Med blog, written by Pedro Zuzarte. It starts from the World Health Organization’s position that depression is already the condition contributing most to a person’s overall disability, calculated in DALYs: the sum of years of life lost to premature death (YLL) and years lived with disability (YLD).

References cited in the original article (selection)

  • World Health Organization. Depression and other common mental disorders: global health estimates.
  • Sivertsen H, Bjørkløf GH, Engedal K, Selbæk G, Helvik AS. Depression and quality of life in older persons: a review. Dement Geriatr Cogn Disord. 2015;40(5-6):311-39.
  • Laursen TM, Musliner KL, Benros ME, Vestergaard M, Munk-Olsen T. Mortality and life expectancy in persons with severe unipolar depression. J Affect Disord. 2016;193:203-7.
  • Jia H, Zack MM, Thompson WW, Crosby AE, Gottesman II. Impact of depression on quality-adjusted life expectancy (QALE) directly as well as indirectly through suicide. Soc Psychiatry Psychiatr Epidemiol. 2015;50(6):939-49.
  • Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006;9(2):87-98.
  • Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29(6):417-26.
  • Elvsåshagen T, Zuzarte P, Westlye LT, Bøen E, Josefsen D, Boye B, et al. Dentate gyrus-cornu ammonis (CA) 4 volume is decreased and associated with depressive episodes and lipid peroxidation in bipolar II disorder: longitudinal and cross-sectional analyses. Bipolar Disord. 2016.
  • Zuzarte P, Scola G, Duong A, Kostiw K, Figueira ML, Costa-Vitali A. NT-proBNP is a potential mediator between reduced ejection fraction and depression in patients with heart failure. J Psychiatr Res. 2018;104:8-15.

Zuzarte P. A importância de tratar a depressão quando já se considera a patologia que mais contribui para a incapacidade global de um indivíduo. Live-Med [Internet]. 2020 nov 27. Original page no longer available.

A psychiatric assessment can be the first step.

Book an appointment

How a consultation works

If you are looking for psychedelic therapy, KETAMED is the clinic dedicated to this field.

Discover KETAMED (opens in a new tab)

Follow KETAMED: Instagram (opens in a new tab) · Facebook (opens in a new tab)